 |
 Video: What is a Stock Split?
|
|
|
| Protagenic Therapeutic is a development stage biopharmaceutical company focusing on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Co.'s proprietary compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Additionally, Co. is engaged in the research and development of follow-on compounds in the TCAP family. Co. is performing clinical trials to obtain Food and Drug Administration approval and commercialization of its product. According to our PTIX split history records, Protagenic Therapeutics has had 2 splits. | |
|
Protagenic Therapeutics (PTIX) has 2 splits in our PTIX split history database. The first split for PTIX took place on September 16, 1997. This was a 3 for 2
split, meaning for each 2
shares of PTIX owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 1500 share position following the split. PTIX's second split took place on September 02, 1999. This was a 3 for 2
split, meaning for each 2
shares of PTIX owned pre-split, the shareholder now owned 3 shares. For example, a 1500 share position pre-split, became a 2250 share position following the split.
When a company such as Protagenic Therapeutics splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the PTIX split history from start to finish, an original position size of 1000 shares would have turned into 2250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Protagenic Therapeutics shares, starting with a $10,000 purchase of PTIX, presented on a split-history-adjusted basis factoring in the complete PTIX split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/27/2021 |
|
| End date: |
01/27/2023 |
|
| Start price/share: |
$2.26 |
|
| End price/share: |
$0.59 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-73.88% |
|
| Average Annual Total Return: |
-53.50% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$2,611.58 |
|
| Years: |
1.75 |
|
|
|
| Date |
Ratio |
| 09/16/1997 | 3 for 2
| | 09/02/1999 | 3 for 2
|
|
|
Free PTIX Email Alerts:
